Seegene and Hologic to jointly develop multiplex molecular diagnostic assay

6 November 2016 (Last Updated November 6th, 2016 18:30)

Seegene has entered into a worldwide collaboration agreement with Hologic to develop and supply multiplex real-time PCR reagents for the Hologic Panther Fusion system.

Seegene has entered into a worldwide collaboration agreement with Hologic to develop and supply multiplex real-time PCR reagents for the Hologic Panther Fusion system.

Under the agreement, Seegene will be responsible for developing multiplex assays based on DPO, TOCE, and MuDT technologies to be used for Panther Fusion system, Hologic's next generation molecular diagnostics platform.

Hologic will obtain the worldwide commercialisation rights of these assays.

"We expect to accelerate technological standardisation in the MDx market by building up capabilities of assay development applying on various platforms."

Financial terms of the agreement were not disclosed.

Hologic Diagnostic president Tom West said, "We are pleased to partner with Seegene and incorporate their innovative technologies with our system.

"Seegene's multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic's Panther Fusion system and strengthening its leadership position in the molecular diagnostic market."

The Panther system is a fully automated sample-to-answer instrument designed to eliminate the requirement for batch processing while automating all aspects of nucleic acid testing on a single, integrated platform.

Once commercialised, the Fusion expansion module will provide laboratory customers a seamless evolution of their Panther system and allow expanded assay menu with real-time PCR capabilities in a single-unit-dose format.

Seegene expands effort to continually develop and commercialise high multiplex PCR technologies that enable more accurate and cost-effective molecular diagnostics.  MuDT technology offers perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel.

Seegene founder and CEO Dr. Jong - Yoon Chun said, "Our agreement with Hologic represents another meaningful milestone to Seegene's global expansion initiatives in the molecular diagnostics market.

"We expect to accelerate technological standardisation in the MDx market by building up capabilities of assay development applying on various platforms."

The firm is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx).

Its core enabling technologies, DPO, TOCE, and MuDT, are the basis of M-MoDx tests that can simultaneously detect multiple targets with sensitivity, specificity and reproducibility.